Aims: To develop a specific radioimmunoassay for the routine determination of serum vitamin B12. Methods: Antisera were raised in rabbits by immunisation with the monocarboxylic acid derivative of cyanocobalamin coupled to human serum albumin. Antibody titres and affinities were determined and the antiserum giving the highest binding affinity constant, Ka, was used to develop the assay protocol. Donkey-anti-rabbit gamma globulin-coated magnetisable particles were used to separate the bound from free vitamin B12. The considerable cobalamin binding capacity of human serum was destroyed by autoclaving in acetate-cyanide buffer. Sixty samples were assayed by the radioimmunoassay (RIA) and the Lactobacillus leichmannii assay. Recovery and cross-reactivity experiments were performed.
The first in vitro measurements of vitamin B12 in serum were by microbiological assays, developed in the 1950s and based on the requirements of certain organisms for corrinoids as growth factors.''0 Although sensitive, cheap, and simple in concept, accurate and reproducible results require care and experience. The disadvantages include long incubation times, possible microbial contamination, and suppression of growth by antibiotics and cytotoxic drugs." Over the past 25 years microbiological assays have been replaced in most laboratories by radioisotope dilution assays (RIDA), using intrinsic factor (IF) and R-protein as binders. In the 1970s RIDAs achieved popularity because of claims that they were technically simpler, more accurate and reproducible than microbiological assays, free from microbial and iatrogenic interference, and commercially available as kits. Several vitamin B12 binders and separation systems have been used. '212 Comparisons of RIDAs with microbiological assays have shown discrepancies attributable to biologically inactive cobalamin analogues.2224 High performance liquid chromatography provides a rapid and reproducible means of characterising physiological cobalamins but is not sufficiently sensitive to detect the concentrations found in human serum. 2526 The availability of an immunoassay specific for vitamin B12 and free from interference by cobalamin analogues, related corrinoids, or non-specific binders would be of value for the routine measurement of serum vitamin B12.
Although radioimmunoassay methods27"3 have been developed, they have not been widely used due to difficulties in preparing appropriate antibodies. We present here details of an immunoassay for the determination of serum vitamin B12 concentrations using antibodies raised in rabbits against the monocarboxylic acid derivative of cyanocobalamin conjugated to human serum albumin.
Methods
Cyanocobalamin (crystalline, pure; Sigma) was subjected to mild acid hydrolysis with 0 4 M hydrochloric acid (BDH) and the monocarboxylic acid derivative purified on a column (2-5 x 56 cm) of QAE-Sephadex A-25 (Pharmacia LKB). The vitamin B12-human serum albumin (HSA, purified, lophilised; Behringwerke AG) conjugate was prepared by a modification of the method of Ahrenstedt and Thorell."2 The addition of the spacer molecule into the conjugate was omitted and TRIS buffer (AnalaR, BDH) was used instead of pyridine, followed by desalting on Sephadex G-15 (Pharmacia). The conjugate was then lyophilised, redissolved in deionised water to 1-5 mg/ ml and stored at -70°C. Vitamin B12-HSA conjugate, 1-5 mg in 1-0 ml of deionised water, was emulsified with 1 0 ml Freund's Complete Adjuvant and injected intradermally, at multiple sites, on the backs of five adult rabbits. Blood samples were collected monthly from the marginal ear vein and the antibody titres were determined. Injections were at monthly intervals over four months.
Four bovine serum albumin (BSA) preparations were evaluated for use in the assay diluent: (i) 98-99% BSA; (ii) RIA garde BSA; (iii) vitamin B12 and B12 binding factor deficient BSA (all from Sigma); and (iv) human plasma protein fraction (Blood Products Laboratory). Diluents contained 0-5% w/v BSA, with and without 0-2% v/v Tween-20.
Serial dilutions of antiserum were made in 0 05 M phosphate buffered saline (PBS) (pH 7-0) containing 0-5% BSA (98-99% albumin; Sigma) and 0-1% sodium azide. Each antiserum dilution (0-35 ml) was pipetted in duplicate into polystyrene assay tubes (75 x 12 mm Sarstedt) with 0 05 ml PBS and 0 1 ml 44 pmol/l cyano (Co57) cobalamin (CT2, high specific activity, 370 KBq/ml; Amersham International Ltd.) and incubated at 200C for 16 hours. Magnetisable particles (0 5 ml, 2 g/l),* freshly resuspended and intermittently mixed to avoid settling out, was added to all tubes, except the "total activity" tubes. After mixing thoroughly the tubes were left standing, undisturbed, at 20°C for 30 minutes, then placed over a Magnetic Separator (Serono Diagnostics Ltd.) for five minutes. While standing on the magnets the supernatants were aspirated to waste using a Venturi water-jet pump. The pellets of magnetisable particles were resuspended in saline (1 -5 ml) and the tubes were again left to stand on the magnets for five minutes. The supematants were aspirated to waste and the tracer bound to the magnetisable particles was measured using an NE 1600 multiple well-type gamma counter. Included in each assay were two "total activity" tubes, containing only tracer and two "blank" or non-specific binding tubes, containing no antiserum. The titre of each antiserum was expressed as the antiserum dilution which bound 50% of the cyano (Co57) cobalamin tracer added.
The rabbit antisera were diluted in PBS as follows (table 3) show that the B12 binding capacity of the human serum and the non-immune rabbit serum were no longer evident at dilutions of 1/1000 and 1/10 000, respectively. The non-specific binding value was 1A4%. As the R4 antiserum was diluted 1 in 100 000 for the assay, no interference from endogenous B12 binding proteins could occur. Human sera (vitamin B12 normal range 111-738 pmol/l) cannot be diluted 1 in 1000 because the concentration of vitamin B12 present in normal serum samples would be below 15 pmol/l, the limit of sensitivity (fig 1) . Therefore, the endogenous vitamin B12 binding proteins have to be removed before assay. Sixty sera were assayed by RIA and the L leichmannii microbiological assay. The correlation coefficient was 0-85 (fig 2) . The intrabatch coefficient of variation (CV) of three aliquots of the same serum varied from 12 4 to 20 6%. The interbatch CV was below 22% with the exception of one serum of very low vitamin B12 content, with a range of 16-49 pmol/l, where the CV was 58-2% (table 4) . Table 5 details the results of recovery of exogenous vitamin B12.
The dicyanide cobinamide and hydroxocobalamin curves were not parallel to the cyanocobalamin curve. The cross-reactivity calculated at 80% Bo gave 998 and 8-1% for dicyanide cobinamide and hydroxocobalamin, respectively. Discussion Serum vitamin B12 concentrations are currently determined either by RIDAs or microbiological assay. Results obtained using the first generation RIDAs led Kolhouse et al23 and Cooper and Whitehead24 to suggest that the non-purified vitamin B 12 binding proteins used bound cobalamin analogues which resulted in normal vitamin B12 concentrations being reported for patients with clinical signs of vitamin B12 deficiency. Now, third generation RIDAs, utilising "purified intrinsic factor" or "blocked R-binders", are being produced. Although several RIA methods for the measurement of vitamin B12 have been reported, none is in routine use.
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